Teva Pharma (TEVA) Tops Q1 EPS by 5c; updates guidance

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.53, $0.05 better than the analyst estimate of $0.48. Revenue for the quarter came in at $4 billion versus the consensus estimate of $3.81 billion.

GUIDANCE:

Teva Pharma sees FY2026 EPS of $1.91-$2.11, versus the consensus of $2.68. Teva Pharma sees FY2026 revenue of $16.4-16.8 billion, versus the consensus of $16.497 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
• A. O. Smith CEO Stephen Shafer named chairman